RS52256B2 - Terapeutske upotrebe jedinjenja sa kombinovanim sert, 5-ht3 i 5-ht1a aktivnostima - Google Patents

Terapeutske upotrebe jedinjenja sa kombinovanim sert, 5-ht3 i 5-ht1a aktivnostima

Info

Publication number
RS52256B2
RS52256B2 RS20120087A RSP20120087A RS52256B2 RS 52256 B2 RS52256 B2 RS 52256B2 RS 20120087 A RS20120087 A RS 20120087A RS P20120087 A RSP20120087 A RS P20120087A RS 52256 B2 RS52256 B2 RS 52256B2
Authority
RS
Serbia
Prior art keywords
compounds
therapeutic uses
ht1a activity
sert
combined
Prior art date
Application number
RS20120087A
Other languages
English (en)
Inventor
Nicholas Moore
Marianne Dragheim
Aneil Batra
Jin Chon
Original Assignee
H Lundbeck As
Takeda Pharmaceuticals U S A Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52256(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As, Takeda Pharmaceuticals U S A Inc filed Critical H Lundbeck As
Publication of RS52256B publication Critical patent/RS52256B/sr
Publication of RS52256B2 publication Critical patent/RS52256B2/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20120087A 2007-11-13 2008-11-12 Terapeutske upotrebe jedinjenja sa kombinovanim sert, 5-ht3 i 5-ht1a aktivnostima RS52256B2 (sr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US98771007P 2007-11-13 2007-11-13
DKPA200701607 2007-11-13
US1372207P 2007-12-14 2007-12-14
DKPA200701788 2007-12-14
US9784008P 2008-09-17 2008-09-17
DKPA200801300 2008-09-17
EP08850935.1A EP2219647B2 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (2)

Publication Number Publication Date
RS52256B RS52256B (sr) 2012-10-31
RS52256B2 true RS52256B2 (sr) 2020-11-30

Family

ID=40170671

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20120087A RS52256B2 (sr) 2007-11-13 2008-11-12 Terapeutske upotrebe jedinjenja sa kombinovanim sert, 5-ht3 i 5-ht1a aktivnostima
RS20160756A RS55147B1 (sr) 2007-11-13 2008-11-12 Terapeutske upotrebe jedinjenja koja imaju kombinovanu sert, 5-ht3 i 5-ht1a aktivnost

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20160756A RS55147B1 (sr) 2007-11-13 2008-11-12 Terapeutske upotrebe jedinjenja koja imaju kombinovanu sert, 5-ht3 i 5-ht1a aktivnost

Country Status (30)

Country Link
US (5) US9278096B2 (sr)
EP (3) EP2219647B2 (sr)
JP (2) JP5603244B2 (sr)
KR (1) KR101536023B1 (sr)
CN (1) CN102014908A (sr)
AR (1) AR069260A1 (sr)
AT (1) ATE537829T1 (sr)
AU (1) AU2008323390B2 (sr)
BR (1) BRPI0820474B8 (sr)
CA (1) CA2705163C (sr)
CL (1) CL2008003363A1 (sr)
CO (1) CO6270322A2 (sr)
CY (2) CY1112646T1 (sr)
DK (2) DK2431039T3 (sr)
EA (1) EA027783B1 (sr)
ES (2) ES2379419T5 (sr)
HR (2) HRP20120144T4 (sr)
HU (1) HUE029588T2 (sr)
IL (1) IL205466A (sr)
LT (1) LT2431039T (sr)
MX (1) MX2010004688A (sr)
NZ (1) NZ585247A (sr)
PL (2) PL2431039T3 (sr)
PT (2) PT2219647E (sr)
RS (2) RS52256B2 (sr)
SG (1) SG10201405001XA (sr)
SI (2) SI2219647T2 (sr)
TW (1) TW200932233A (sr)
WO (1) WO2009062517A1 (sr)
ZA (1) ZA201003350B (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
PL2470166T3 (pl) * 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HUE036637T2 (hu) * 2011-01-27 2018-07-30 Neuren Pharmaceuticals Ltd Autizmus spektrumbetegségek kezelése glicil-L-2-metilprolil-L-glutaminsavval
WO2013012038A1 (ja) 2011-07-21 2013-01-24 学校法人名城大学 うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
MX362886B (es) * 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
WO2014191548A1 (en) * 2013-05-31 2014-12-04 Lek Pharmaceuticals D.D. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CA2933733A1 (en) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CA2992161A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ES2280595T3 (es) * 2001-12-20 2007-09-16 H. Lundbeck A/S Derivados de ariloxifenilo y arilsulfanilfenilo.
ATE406894T1 (de) 2003-04-04 2008-09-15 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
PL2470166T3 (pl) 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny

Also Published As

Publication number Publication date
EP2431039A1 (en) 2012-03-21
CO6270322A2 (es) 2011-04-20
PT2431039T (pt) 2016-09-29
EP2219647B1 (en) 2011-12-21
US20110201617A1 (en) 2011-08-18
HRP20120144T1 (en) 2012-04-30
IL205466A (en) 2014-06-30
HRP20161121T1 (hr) 2017-01-27
SI2219647T1 (sl) 2012-06-29
WO2009062517A1 (en) 2009-05-22
ES2591110T3 (es) 2016-11-24
AU2008323390B2 (en) 2013-10-24
CY1117978T1 (el) 2017-05-17
RS55147B1 (sr) 2016-12-30
ZA201003350B (en) 2011-08-31
US20240082239A1 (en) 2024-03-14
EP2219647B2 (en) 2020-07-29
NZ585247A (en) 2012-03-30
US9278096B2 (en) 2016-03-08
BRPI0820474B1 (pt) 2020-08-04
BRPI0820474B8 (pt) 2021-05-25
DK2431039T3 (en) 2016-09-26
CN102014908A (zh) 2011-04-13
SG10201405001XA (en) 2014-10-30
HRP20120144T4 (hr) 2020-11-13
JP2014193891A (ja) 2014-10-09
RS52256B (sr) 2012-10-31
PL2431039T3 (pl) 2016-12-30
DK2219647T4 (da) 2020-09-28
US11628166B2 (en) 2023-04-18
CA2705163A1 (en) 2009-05-22
EA201070598A1 (ru) 2010-10-29
EP2431039B1 (en) 2016-07-20
PT2219647E (pt) 2012-03-16
IL205466A0 (en) 2010-12-30
KR20100099115A (ko) 2010-09-10
AU2008323390A1 (en) 2009-05-22
US9744166B2 (en) 2017-08-29
ATE537829T1 (de) 2012-01-15
AR069260A1 (es) 2010-01-06
CY1112646T1 (el) 2016-02-10
EA027783B1 (ru) 2017-09-29
LT2431039T (lt) 2016-10-10
US20160228430A1 (en) 2016-08-11
CA2705163C (en) 2013-02-12
JP5841636B2 (ja) 2016-01-13
JP2011503125A (ja) 2011-01-27
MX2010004688A (es) 2010-09-09
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
KR101536023B9 (ko) 2023-03-29
SI2219647T2 (sl) 2020-11-30
CL2008003363A1 (es) 2009-06-05
DK2219647T3 (da) 2012-03-19
ES2379419T3 (es) 2012-04-25
EP2219647A1 (en) 2010-08-25
SI2431039T1 (sl) 2017-01-31
JP5603244B2 (ja) 2014-10-08
KR101536023B1 (ko) 2015-07-10
EP3115050A1 (en) 2017-01-11
HUE029588T2 (en) 2017-03-28
BRPI0820474A2 (pt) 2017-05-23
ES2379419T5 (es) 2021-05-04
US20210093631A1 (en) 2021-04-01
TW200932233A (en) 2009-08-01

Similar Documents

Publication Publication Date Title
RS52256B2 (sr) Terapeutske upotrebe jedinjenja sa kombinovanim sert, 5-ht3 i 5-ht1a aktivnostima
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
IL210195A0 (en) Benzoxazines, benzothazines, and related compounds having nos inhibitory activity
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
HK1145319A1 (en) Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
PL2342329T3 (pl) Warianty beta-glukozydazy o polepszonej aktywności i ich zastosowania
GB0714030D0 (en) The use of type-B lantibiotic-based compounds having antimicrobial activity
PL2238119T3 (pl) Chinazoliny i pokrewne związki heterocykliczne i ich zastosowanie terapeutyczne
GB0915948D0 (en) Surgical, therapeutic or diagnostic tool
EP2351732A4 (en) NEW RAMALINE CONNECTION AND ITS USE
IL207799A0 (en) Azetidine-derived compounds, preparation method therefor and therapeutic use of same
IL220586A (en) Carboxamide compound, a pharmaceutical composition containing it and its use
GB0710981D0 (en) New Therapeutic use
HK1196271A1 (zh) 粘土基的矯味治療組合物
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
GB0704334D0 (en) Patient bed
IL209403A0 (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity
GB0520393D0 (en) New medical uses
GB0601552D0 (en) New medical uses
GB0716122D0 (en) New medical use
GB0703788D0 (en) New therapeutic use
GB0710099D0 (en) New Therapeutic use
GB0710096D0 (en) New Therapeutic use
GB0710098D0 (en) New Therapeutic use
GB0714336D0 (en) new therapeutic use